RE: TRANSITION THERAPEUTICS ROBUST PIPELINE
Atually he is turtle.......he has made it quite clear that hepc will not be moving forward unless partnered and that they still seek to partner the IET Technology to that disease indication.
This is right along Transitions Business Modelling that manages the higher Risk and costs associated with the later stage Clinicals. I would suggest that anyone not on board with Transitions business model to Sell. Not for those without higher Risk tolerance or understanding of the BM.
GPP all.